The parallels to the CCR5 delta32 mutation as a protective factor in infection by HIV and the successful development of a CCR5 inhibitor to treat AIDS are striking and we envisage that development of a DARC inhibitor might also work for P. vivax-induced malaria. The gene discussed is CCR5; the disease is malaria.